ATOPIC DERMATITIS: SKIN AND IMMUNE RESPONSE TO REDUCED ALLERGEN EXPOSURE

特应性皮炎:皮肤和免疫对减少过敏原暴露的反应

基本信息

  • 批准号:
    7951462
  • 负责人:
  • 金额:
    $ 13.16万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-03-01 至 2010-02-28
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Elevated total IgE and specific IgE to allergens from diverse sources including cat and house dust mite (HDM) have been demonstrated in patients with atopic dermatitis (AD). Improvement of eczematous lesions has been reported when patients are admitted to the hospital, which represents an "allergen-free" environment. Severe clinical disease in AD patients has been attributed to suppression of the immune response or immune dysregulation. We have recently demonstrated that the immune response to allergens is altered at both the B-cell and T-cell level in allergic patients with AD. We will test the hypothesis that allergen avoidance in subjects with IgE ab to common allergens is associated with improvement of skin condition and changes in the immune response to allergens derived from HDM and cat. Serum antibodies (IgG and IgE) and T cell responses to common allergens and allergen-derived peptides will be monitored at weekly intervals (3 weeks maximum) in AD patients who receive a complete allergen avoidance regimen in a hospital environment. Detailed analysis of in vitro T cell responses will include measurement of allergen-stimulated proliferation and cytokine production, expression of cell surface markers by flow cytometry and enumeration of different T cell subsets. Data will be compared at each time point within each individual in order to determine changes which occur during allergen avoidance. Results will also be compared between groups of AD patients with and without IgE ab to common allergens. Statisical tests will include student's t test, cross-validated linear discriminant analysis, and linear regression analysis.
这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者(PI)可能从另一个NIH来源获得了主要资金, 因此可以在其他CRISP条目中表示。所列机构为 研究中心,而研究中心不一定是研究者所在的机构。 特应性皮炎(AD)患者的总IgE和特异性IgE水平升高,这些过敏原来自不同的来源,包括猫和屋尘螨(HDM)。 据报道,当患者入院时,湿疹性病变得到改善,这代表了“无过敏原”的环境。 AD患者的严重临床疾病归因于免疫应答抑制或免疫失调。 我们最近已经证明,过敏性AD患者对过敏原的免疫应答在B细胞和T细胞水平上都发生了改变。 我们将检验这样的假设,即对常见过敏原具有IgE抗体的受试者的过敏原回避与皮肤状况的改善以及对源自HDM和猫的过敏原的免疫应答的变化相关。每周监测一次对常见过敏原和过敏原衍生肽的IgG和IgE和T细胞应答(最多3周)在医院环境中接受完全过敏原避免方案的AD患者中。 体外T细胞应答的详细分析将包括测量变应原刺激的增殖和细胞因子产生、通过流式细胞术表达细胞表面标志物和计数不同的T细胞亚群。 将在每个时间点比较每个个体的数据,以确定在过敏原避免期间发生的变化。 结果也将比较AD患者组之间的IgE抗体和不常见的过敏原。 统计检验包括学生t检验、交叉验证线性判别分析和线性回归分析。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Judith A Woodfolk其他文献

Use of a novel air cleaner to monitor airborne allergen
  • DOI:
    10.1016/s0091-6749(02)81248-9
  • 发表时间:
    2002-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Natalie J Custis;Judith A Woodfolk;John W Vaughan;Thomas AE Platts-Mills
  • 通讯作者:
    Thomas AE Platts-Mills

Judith A Woodfolk的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Judith A Woodfolk', 18)}}的其他基金

Immune Programs and Related T Cell Mechanisms of Pulmonary Complications After COVID-19 Illness
COVID-19 疾病后肺部并发症的免疫程序和相关 T 细胞机制
  • 批准号:
    10886167
  • 财政年份:
    2023
  • 资助金额:
    $ 13.16万
  • 项目类别:
Protective and Pathogenic T Cells Responding to SARS-CoV-2 in Health and Disease
健康和疾病中对 SARS-CoV-2 做出反应的保护性和致病性 T 细胞
  • 批准号:
    10218954
  • 财政年份:
    2021
  • 资助金额:
    $ 13.16万
  • 项目类别:
Protective and Pathogenic T Cells Responding to SARS-CoV-2 in Health and Disease
健康和疾病中对 SARS-CoV-2 做出反应的保护性和致病性 T 细胞
  • 批准号:
    10488185
  • 财政年份:
    2021
  • 资助金额:
    $ 13.16万
  • 项目类别:
Regulation of TSLP receptor expression and function in eczema in mice and man
小鼠和人湿疹中 TSLP 受体表达和功能的调节
  • 批准号:
    8651423
  • 财政年份:
    2011
  • 资助金额:
    $ 13.16万
  • 项目类别:
Regulation of TSLP receptor expression and function in eczema in mice and man
小鼠和人湿疹中 TSLP 受体表达和功能的调节
  • 批准号:
    8106840
  • 财政年份:
    2011
  • 资助金额:
    $ 13.16万
  • 项目类别:
Regulation of TSLP receptor expression and function in eczema in mice and man
小鼠和人湿疹中 TSLP 受体表达和功能的调节
  • 批准号:
    8460063
  • 财政年份:
    2011
  • 资助金额:
    $ 13.16万
  • 项目类别:
Regulation of TSLP receptor expression and function in eczema in mice and man
小鼠和人湿疹中 TSLP 受体表达和功能的调节
  • 批准号:
    8244445
  • 财政年份:
    2011
  • 资助金额:
    $ 13.16万
  • 项目类别:
ATOPIC DERMATITIS: SKIN AND IMMUNE RESPONSE TO REDUCED ALLERGEN EXPOSURE
特应性皮炎:皮肤和免疫对减少过敏原暴露的反应
  • 批准号:
    8167150
  • 财政年份:
    2010
  • 资助金额:
    $ 13.16万
  • 项目类别:
ATOPIC DERMATITIS: SKIN AND IMMUNE RESPONSE TO REDUCED ALLERGEN EXPOSURE
特应性皮炎:皮肤和免疫对减少过敏原暴露的反应
  • 批准号:
    7718542
  • 财政年份:
    2008
  • 资助金额:
    $ 13.16万
  • 项目类别:
ATOPIC DERMATITIS: SKIN AND IMMUNE RESPONSE TO REDUCED ALLERGEN EXPOSURE
特应性皮炎:皮肤和免疫对减少过敏原暴露的反应
  • 批准号:
    7606686
  • 财政年份:
    2007
  • 资助金额:
    $ 13.16万
  • 项目类别:

相似海外基金

Development of therapeutic monoclonal antibodies aiming at an application and the immunosuppression to an allergic disease of Fingolimod
针对芬戈莫德过敏性疾病的应用和免疫抑制的治疗性单克隆抗体的开发
  • 批准号:
    16K08409
  • 财政年份:
    2016
  • 资助金额:
    $ 13.16万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Prevention of Allergic Rhinitis with Topical Immunomodulating Antibodies
使用外用免疫调节抗体预防过敏性鼻炎
  • 批准号:
    8201881
  • 财政年份:
    2011
  • 资助金额:
    $ 13.16万
  • 项目类别:
Development of antibodies to Il-13 receptor and their preclinical testing in a sheep model for human allergic asthma
IL-13受体抗体的开发及其在人类过敏性哮喘绵羊模型中的临床前测试
  • 批准号:
    nhmrc : 310603
  • 财政年份:
    2004
  • 资助金额:
    $ 13.16万
  • 项目类别:
    Early Career Fellowships
B-1 B cells as a source of polyreactive IgE antibodies, in allergic individuals
B-1 B 细胞作为过敏个体中多反应性 IgE 抗体的来源
  • 批准号:
    nhmrc : 209590
  • 财政年份:
    2002
  • 资助金额:
    $ 13.16万
  • 项目类别:
    NHMRC Project Grants
IgE antibodies to the mammalian oligosaccharide galactose-alpha-1, 3-galactose (alpha-gal): immunology, epidemiology and relevance to allergic and inflammatory disease
哺乳动物寡糖半乳糖-α-1, 3-半乳糖 (α-gal) 的 IgE 抗体:免疫学、流行病学以及与过敏性和炎症性疾病的相关性
  • 批准号:
    10518418
  • 财政年份:
    1984
  • 资助金额:
    $ 13.16万
  • 项目类别:
IgE antibodies to the mammalian oligosaccharide galactose-alpha-1, 3-galactose (alpha-gal): immunology, epidemiology and relevance to allergic and inflammatory disease
哺乳动物寡糖半乳糖-α-1, 3-半乳糖 (α-gal) 的 IgE 抗体:免疫学、流行病学以及与过敏性和炎症性疾病的相关性
  • 批准号:
    10119751
  • 财政年份:
    1984
  • 资助金额:
    $ 13.16万
  • 项目类别:
IgE antibodies to the mammalian oligosaccharide galactose-alpha-1, 3-galactose (alpha-gal): immunology, epidemiology and relevance to allergic and inflammatory disease
哺乳动物寡糖半乳糖-α-1, 3-半乳糖 (α-gal) 的 IgE 抗体:免疫学、流行病学以及与过敏性和炎症性疾病的相关性
  • 批准号:
    10425338
  • 财政年份:
    1984
  • 资助金额:
    $ 13.16万
  • 项目类别:
IgE antibodies to the mammalian oligosaccharide galactose-alpha-1, 3-galactose (alpha-gal): immunology, epidemiology and relevance to allergic and inflammatory disease
哺乳动物寡糖半乳糖-α-1, 3-半乳糖 (α-gal) 的 IgE 抗体:免疫学、流行病学以及与过敏性和炎症性疾病的相关性
  • 批准号:
    10190780
  • 财政年份:
    1984
  • 资助金额:
    $ 13.16万
  • 项目类别:
MONOCLONAL ANTIBODIES FROM ALLERGIC PATIENTS
来自过敏患者的单克隆抗体
  • 批准号:
    3960798
  • 财政年份:
  • 资助金额:
    $ 13.16万
  • 项目类别:
MONOCLONAL ANTIBODIES FROM ALLERGIC PATIENTS
来自过敏患者的单克隆抗体
  • 批准号:
    4688732
  • 财政年份:
  • 资助金额:
    $ 13.16万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了